Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.

Antiandrogens are initially effective in controlling prostate cancer (CaP), the second most common cancer in men, but resistance, associated with the loss of androgen-regulated cell cycle control, is a major problem. At present there is no effective treatment for androgen-independent prostate cancer (AIPC). Cellular proliferation is driven by cyclin-dependent kinases (CDKs) with kinase inhibitors (for example, p27) applying the breaks. We present the first investigation of the therapeutic potential of CDK inhibitors, using the guanine-based CDK inhibitor NU2058 (CDK2 IC(50)=17 microM, CDK1 IC(50)=26 microM), in comparison with the antiandrogen bicalutamide (Casodex) in AIPC cells. A panel of AIPC cells was found to be resistant to Casodex-induced growth inhibition, but with the exception of PC3 (GI(50)=38 microM) and CWR22Rv1 (GI(50)=46 microM) showed similar sensitivity to NU2058 (GI(50)=10-17 microM) compared to androgen-sensitive LNCaP cells (GI(50)=15 microM). In LNCaP cells and their Casodex-resistant derivative, LNCaP-cdxR, growth inhibition by NU2058 was accompanied by a concentration-dependent increase in p27 levels, reduced CDK2 activity and pRb phosphorylation, a decrease in early gene expression and G1 cell cycle phase arrest in both cell lines. In response to Casodex, there were similar observations in LNCaP cells (GI(50)=6+/-3 microM Casodex) but not in LNCaP-cdxR cells (GI(50)=24+/-5 microM Casodex).
AuthorsA C Rigas, C N Robson, N J Curtin
JournalOncogene (Oncogene) Vol. 26 Issue 55 Pg. 7611-9 (Dec 6 2007) ISSN: 1476-5594 [Electronic] England
PMID17599054 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Androgens
  • Anilides
  • NU2058
  • Nitriles
  • Protein Kinase Inhibitors
  • Retinoblastoma Protein
  • Tosyl Compounds
  • Cyclin-Dependent Kinase Inhibitor p27
  • Guanine
  • bicalutamide
  • CDC2 Protein Kinase
  • Cyclin-Dependent Kinase 2
  • Cyclin-Dependent Kinases
  • Androgens (metabolism)
  • Anilides (therapeutic use)
  • CDC2 Protein Kinase (antagonists & inhibitors)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cyclin-Dependent Kinase 2 (antagonists & inhibitors)
  • Cyclin-Dependent Kinase Inhibitor p27 (metabolism)
  • Cyclin-Dependent Kinases (antagonists & inhibitors)
  • Guanine (analogs & derivatives, therapeutic use)
  • Humans
  • Male
  • Nitriles (therapeutic use)
  • Phosphorylation (drug effects)
  • Prostatic Neoplasms (drug therapy)
  • Protein Kinase Inhibitors (therapeutic use)
  • Retinoblastoma Protein (metabolism)
  • Tosyl Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: